KR20230047425A - 항혈소판 약물 및 이의 용도 - Google Patents

항혈소판 약물 및 이의 용도 Download PDF

Info

Publication number
KR20230047425A
KR20230047425A KR1020237007048A KR20237007048A KR20230047425A KR 20230047425 A KR20230047425 A KR 20230047425A KR 1020237007048 A KR1020237007048 A KR 1020237007048A KR 20237007048 A KR20237007048 A KR 20237007048A KR 20230047425 A KR20230047425 A KR 20230047425A
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237007048A
Other languages
English (en)
Korean (ko)
Inventor
지키앙 구
유안차오 장
공신 헤
카이 호우
하오 우
Original Assignee
상하이 큐어진 파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 큐어진 파마슈티컬 컴퍼니 리미티드 filed Critical 상하이 큐어진 파마슈티컬 컴퍼니 리미티드
Priority to KR1020257016343A priority Critical patent/KR102906376B1/ko
Publication of KR20230047425A publication Critical patent/KR20230047425A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020237007048A 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도 Pending KR20230047425A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257016343A KR102906376B1 (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105513 2020-07-29
CN2020105513 2020-07-29
PCT/CN2021/108875 WO2022022559A1 (en) 2020-07-29 2021-07-28 Antiplatelet drugs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257016343A Division KR102906376B1 (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20230047425A true KR20230047425A (ko) 2023-04-07

Family

ID=80037185

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237007048A Pending KR20230047425A (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도
KR1020257016343A Active KR102906376B1 (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257016343A Active KR102906376B1 (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도

Country Status (14)

Country Link
US (2) US12410132B2 (https=)
EP (2) EP4342532B1 (https=)
JP (1) JP2023535815A (https=)
KR (2) KR20230047425A (https=)
CN (4) CN119552111B (https=)
AR (1) AR123078A1 (https=)
AU (1) AU2021317436A1 (https=)
BR (1) BR112023001595A2 (https=)
CA (1) CA3186645A1 (https=)
ES (1) ES3046366T3 (https=)
IL (1) IL299979A (https=)
MX (1) MX2023001232A (https=)
TW (1) TW202214609A (https=)
WO (1) WO2022022559A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532A (zh) * 2023-06-29 2023-09-29 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108300A1 (zh) * 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
WO2025108307A1 (zh) * 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
JP2008505126A (ja) * 2004-07-07 2008-02-21 メディキュア インターナショナル インコーポレイテッド 血小板凝集薬を用いる併用療法
CA2873094A1 (en) * 2012-05-07 2013-11-14 Cellixbio Private Limited Prodrugs of anti-platelet agents
US9376444B2 (en) * 2012-08-03 2016-06-28 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
NO2721243T3 (https=) * 2014-10-01 2018-10-20
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN119019320B (zh) 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061B (zh) 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Also Published As

Publication number Publication date
WO2022022559A1 (en) 2022-02-03
AU2021317436A1 (en) 2023-02-23
IL299979A (en) 2023-03-01
US20250333382A1 (en) 2025-10-30
CN119552111B (zh) 2026-01-02
CN116194459A (zh) 2023-05-30
EP4188935A4 (en) 2024-07-17
ES3046366T3 (en) 2025-12-01
EP4342532A3 (en) 2024-07-17
CN119033782A (zh) 2024-11-29
EP4342532A2 (en) 2024-03-27
AR123078A1 (es) 2022-10-26
CN119552111A (zh) 2025-03-04
US12410132B2 (en) 2025-09-09
CN119033782B (zh) 2025-04-25
MX2023001232A (es) 2023-05-15
CN117343000A (zh) 2024-01-05
US20240279178A1 (en) 2024-08-22
JP2023535815A (ja) 2023-08-21
EP4342532C0 (en) 2025-09-03
CA3186645A1 (en) 2022-02-03
BR112023001595A2 (pt) 2023-04-04
TW202214609A (zh) 2022-04-16
KR20250073569A (ko) 2025-05-27
EP4342532B1 (en) 2025-09-03
EP4188935A1 (en) 2023-06-07
KR102906376B1 (ko) 2025-12-30

Similar Documents

Publication Publication Date Title
KR102906376B1 (ko) 항혈소판 약물 및 이의 용도
JP7221861B2 (ja) オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
KR20240142492A (ko) 항혈소판 약물의 약학적 조성물 및 이의 용도
EP3209652B1 (en) Tricyclic atropisomer compounds
AU2017254266B2 (en) Prodrug of amino acid derivative
CN107148409B (zh) 经取代的二环化合物
JP4982482B2 (ja) Ｈｉｖインテグラ−ゼ阻害剤
WO2021231726A1 (en) Enpp1 modulators and uses thereof
JP7814359B2 (ja) 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用
KR102797099B1 (ko) 2-[(3r)-3-메틸모르폴린-4-일]-4-(1-메틸-1h-피라졸-5-일)-8-(1h-피라졸-5-일)-1,7-나프티리딘의 제조 방법
RU2841656C1 (ru) Антитромбоцитарные лекарственные средства и их применение
US11834413B2 (en) Antiplatelet drugs and uses thereof
HK40117914B (zh) 抗血小板药物和其用途
HK40117914A (zh) 抗血小板药物和其用途
HK40090099A (zh) 抗血小板药物和其用途
CS142991A3 (en) Alpha-oxopyrrolo/2,3-b/indolacetic acids, their esters, amides and analogs, process for their preparation and their application as medicaments
WO2023138621A1 (en) Atr inhibitors and uses thereof
WO2025007743A1 (en) Sting agonists and uses thereof
JP2023544037A (ja) ビヘテロアリール化合物およびその結晶形態を調製するための方法
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
CN117545742A (zh) 嘧啶类化合物、包含其的药物组合物、其制备方法及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902